E-LIB Suche - Ergebnisse für: Van Cutsem, E.

1

An open-label study of pemigatinib in cholangiocarcinoma: f..:

Vogel, A. ; Sahai, V. ; Hollebecque, A....
ESMO Open. 9 (2024) 6 - p. 103488 , 2024

Link: https://doi.org/10.1016/..

2

77P Chronologic improvement in survival of first-line oxali..:

Takeda, Y. ; Yamazaki, K. ; Saltz, L....
Annals of Oncology. 35 (2024) - p. S38 , 2024

Link: https://doi.org/10.1016/..

3

323P NALIRIFOX versus nab-paclitaxel and gemcitabine (Gem+N..:

Macarulla Mercade, T. ; Pazo Cid, R.A. ; Womack, M....
Annals of Oncology. 35 (2024) - p. S135-S136 , 2024

Link: https://doi.org/10.1016/..

4

2O Health-related quality of life (HRQoL) with first-line (..:

Lonardi, S. ; André, T. ; Arnold, D....
Annals of Oncology. 35 (2024) - p. S1-S2 , 2024

Link: https://doi.org/10.1016/..

5

329P Nadunolimab, a first-in-class monoclonal antibody agai..:

Van Cutsem, E. ; Ochsenreither, S. ; Collignon, J.J....
Annals of Oncology. 35 (2024) - p. S138-S139 , 2024

Link: https://doi.org/10.1016/..

6

7P Molecular targeted therapies based on metastatic site in..:

Raeisi, M. ; Cohen, R. ; Chibaudel, B....
ESMO Open. 9 (2024) - p. 102262 , 2024

Link: https://doi.org/10.1016/..

7

Fluoropyrimidine type, patient age, tumour sidedness and mu..:

Karapetis, C. S. ; Liu, H. ; Sorich, M. J....
British Journal of Cancer. 130 (2024) 8 - p. 1269-1278 , 2024

Link: https://doi.org/10.1038/..

8

Impact of KRASG12 mutations on survival with trifluridine/t..:

Tabernero, J. ; Taieb, J. ; Fakih, M....
ESMO Open. 9 (2024) 3 - p. 102945 , 2024

Link: https://doi.org/10.1016/..

9

Tislelizumab versus chemotherapy as second-line treatment f..:

Ajani, J. ; El Hajbi, F. ; Cunningham, D....
ESMO Open. 9 (2024) 1 - p. 102202 , 2024

Link: https://doi.org/10.1016/..

10

31P Effect of fruquintinib in patients with heavily pretrea..:

Tabernero, J. ; Eng, C. ; Lonardi, S....
Annals of Oncology. 35 (2024) - p. S15-S16 , 2024

Link: https://doi.org/10.1016/..

11

35P Neutropenia and efficacy outcomes in patients with refr..:

Prager, G. ; Tabernero, J. ; Fakih, M....
Annals of Oncology. 35 (2024) - p. S18-S19 , 2024

Link: https://doi.org/10.1016/..

12

395MO Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PB..:

Raymond, E. ; Xu, J. ; Kato, K....
Annals of Oncology. 35 (2024) - p. S159 , 2024

Link: https://doi.org/10.1016/..

13

Fluoropyrimidine-induced hand-foot syndrome and cardiotoxic..:

Punt, C.J.A. ; Heinemann, V. ; Maughan, T....
ESMO Open. 8 (2023) 2 - p. 101199 , 2023

Link: https://doi.org/10.1016/..

14

155P A phase I study exploring the safety and tolerability ..:

Prenen, H. ; Lesimple, T. ; Robert, M....
Immuno-Oncology and Technology. 20 (2023) - p. 100666 , 2023

Link: https://doi.org/10.1016/..

15

A randomized controlled trial of hand/foot-cooling by hilot..:

Coolbrandt, A. ; Tobback, H. ; Govaerts, R....
ESMO Open. 8 (2023) 2 - p. 101205 , 2023

Link: https://doi.org/10.1016/..